GEN | News Highlights:Firms Report Promising Data for Type 1 and 2 Diabetes Candidates at 71st Annual ADA Meeting

Image via WikipediaGEN | News Highlights:Firms Report Promising Data for Type 1 and 2 Diabetes Candidates at 71st Annual ADA Meeting

The American Diabetes Association (ADA) meeting in San Diego included the presentation of new data from Phase III trials evaluating Bristol-Myers Squibb (BMS) and AstraZeneca’s dapagliflozin, Boehringer Ingelheim and Eli Lilly’s linagliptin, and Novo Nordisk’s insulin degludec.

Spherix Announces Positive Type 2 Diabetes News

Image via Wikipedia

PR NewsWire's Coverage of Spherix

Positive Clinical Trial Results were concluded for Type 2 Diabetes. This stock is a buy right now. It is very low priced. Trading was halted today. Expect modest returns tomorrow October 8th.  This is a competitive market for Diabetes Drugs.  Hopefully, getting FDA Approval soon could allow a gain in Market Share.

Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes

New Targets, Dual Agonists Increase Possibilities for Treating Diabetes

Image via Wikipedia Fritz French, Chief Executive Officer, Marcadia Biotech, Carmel, Ind.
Drug Discovery & Development - August 16, 2010

Diabetes is a common chronic disease affecting an estimated 285 million adults worldwide. This number will continue to grow as the population ages and becomes more obese—both risk factors for type 2 diabetes. The diabetes treatment market generated over $25 billion in 2009 and the number of patients is continuously rising.